Advertisement

Guideline-based Management of Patients With Atrial Fibrillation

Published:November 20, 2018DOI:https://doi.org/10.1016/j.nurpra.2018.08.014

      Highlights

      • In 2010, 33.5 million people worldwide diagnosed AF predicted to rise by 5% annually.
      • Symptomatic AF patients report increase in quality of life and exercise tolerance in sinus rhythm.
      • For patients on DOACs, renal function needs to be monitored routinely for change in dose requirement
      • NP-run cardioversion program found high success rates and expedited access to care.
      • Understand lifestyle modifications that can decrease the burden of AF

      Abstract

      Atrial fibrillation (AF) has become a significant public health concern. An epidemiologic study conducted in 2010 estimated there are over 33.5 million people worldwide diagnosed with AF with that number predicted to rise by 5% annually. In the United States, AF is the primary diagnosis in over 500,000 hospital admissions annually. Guideline-based knowledge of treatment options is imperative in decreasing stroke risk, prevention of worsening heart function, and maintaining quality of life. It is also important for nurse practitioners to have this knowledge to make educated treatment recommendations to keep our patients safe and to help them to set realistic expectations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Morillo C.A.
        • Banerjee A.
        • Perel P.
        • Wood D.
        • Jouven X.
        Atrial fibrillation: the current epidemic.
        J Geriatr Cardiol. 2017; 14: 195-203https://doi.org/10.11909/j.issn.1671-5411.2017.03.011
        • Chugh S.S.
        • Havmoeller R.
        • Naryanan K.
        • et al.
        Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study.
        Circulation. 2014; 129: 837-847https://doi.org/10.1161/CIRCULATIONAHA.113.005119
        • Bersohn M.
        The expanding role of nurses in electrophysiology practice.
        JACC Clin Electrophysiol. 2017; 3: 1453-1455https://doi.org/10.1016/j.jacep.2017.07.008
        • Choi M.
        • De Gagne J.C.
        Autonomy of nurse practitioners in primary care: an integrative review.
        J Am Assoc Nurse Pract. 2016; 28: 170-174https://doi.org/10.1002/2327-6924.12288/full
        • Padfield G.J.
        • Steinberg C.
        • Swampillai J.
        • et al.
        Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation.
        Heart Rhythm. 2017; 14: 801-807
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary.
        J Am Coll Cardiol. 2014; 64: 2246-2280
        • Moyer C.B.
        • Norton P.T.
        • Ferguson J.D.
        • Holmes J.W.
        Changes in global and regional mechanics due to atrial fibrillation: insights from a coupled finite-element and circulation model.
        Ann Biomed Eng. 2015; 43: 1600-1613https://doi.org/10.1007/s10439-015-1256-0
        • Kabach M.
        • Zaiem F.
        • Alraies M.C.
        Cardiac amyloidosis presenting with paroxysmal atrial fibrillation.
        QJM. 2015; 108: 819-820https://doi.org/10.1093/qjmed/hcu249
        • Stöllberger C.
        • Finsterer J.
        New oral anticoagulants in patients with atrial fibrillation.
        Lancet. 2014; 384: 23https://doi.org/10.1016/S0140-6736(14)61102-8
      1. Reed B. Beta blockers vs calcium channel blockers for atrial fibrillation rate control: thinking beyond the ED. ALiEM, September 8th, 2014.

      2. Tsiperfal A. Ottoboni Beheiry S. Al-Ahmad A. Natale A. Wang P.J. Cardiac Arrhythmia Management: a Practical Guide for Nurses and Allied Professionals. Wiley, Hoboken, NJ2011
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962
        • Lip G.
        • Mitchell S.A.
        • Liu X.
        • et al.
        Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
        Int J Cardiol. 2016; 204: 88-94
        • Camm A.
        • Amarenco P.
        • Haas S.
        • et al.
        XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
        Eur Heart J. 2016; 37: 1145-1153https://doi.org/10.1093/eurheartj/ehv466
        • Cullen M.W.
        • Stulak J.M.
        • Li Z.
        • et al.
        Left atrial appendage patency at cardioversion after surgical left atrial appendage intervention.
        Ann Thorac Surg. 2016; 101: 675-681
        • Holmes D.R.
        • Kar S.
        • Price M.J.
        • et al.
        Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy.
        J Am Coll Cardiol. 2014; 64: 1-12https://doi.org/10.1016/j.jacc.2014.04.029
        • Halsey C.
        • Chugh A.
        Rate versus rhythm control for atrial fibrillation.
        Cardiol Clin. 2014; 32: 521-531
        • Di Biase L.
        • Mohanty P.
        • Mohanty S.
        • et al.
        Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results From the AATAC Multicenter Randomized Trial.
        Circulation. 2016; 133: 1637-1644https://doi.org/10.1161/CIRCULATIONAHA.115.019406
        • Eckardt L.
        • Pott C.
        Experimental pharmacological targets for the treatment of cardiac arrhythmias: beyond the Vaughn-Williams classification.
        Curr Med Chem. 2014; 21: 1269-1270
        • Qin D.
        • Leef G.
        • Alam M.B.
        • et al.
        Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
        J Cardiol. 2016; 67: 471-476
        • Pratt C.M.
        • Moyé L.A.
        The Cardiac Arrhythmia Suppression Trial.
        Circulation. 1995; 91: 245-247https://doi.org/10.1161/01.CIR.91.1.245
        • Bonora A.
        • Turcato G.
        • Franchi E.
        • et al.
        Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
        Intern Emerg Med. 2017; 12: 853
        • Yarlagadda B.
        • Vuddanda V.
        • Dar T.
        • et al.
        Safety and efficacy of inpatient initiation of dofetilide versus sotalol for atrial fibrillation.
        J Atr Fibrillation. 2017; 10: 1805
      3. Giardina E, Zimetbaum P. Amiodarone: monitoring and management of side effect. UpToDate. https://www-uptodate-com.laneproxy.stanford.edu/contents/amiodarone-monitoring-and-management-of-side-effects. Accessed July 24, 2018.

        • Naccarelli G.V.
        • Kowey P.R.
        The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
        Curr Cardiol Rev. 2014; 10: 303-308https://doi.org/10.2174/1573403X10666140513110247
      4. Passman R, Elsa-Grace Giardina E. Clinical uses of dronedarone. UpToDate. https://www-uptodate-com.laneproxy.stanford.edu/contents/clinical-uses-of-dronedarone?search=dronedarone%20monitoring&source=search_result&selectedTitle=2∼50&usage_type=default&display_rank=4#H155067. Accessed July 26, 2018.

        • Strzelczyk T.
        • Kaplan R.
        • Medler M.
        • Knight B.
        Outcomes associated With electrical cardioversion for atrial fibrillation when performed autonomously by an advanced practice provider.
        JACC Clin Electrophysiol. 2017; 3: 1447-1452https://doi.org/10.1016/j.jacep.2017.04.004
        • Norton L.
        • Tsiperfal A.
        • Cook K.
        • et al.
        Effectiveness and safety of an independently run nurse practitioner outpatient cardioversion program (2009 to 2014).
        Am J Cardiol. 2016; 118: 1842-1846
        • Zaman J.
        • Schricker A.
        • Lalani G.
        • Trikha R.
        • Krummen E.
        • Narayan S.
        Focal impulse and rotor mapping (FIRM): conceptualizing and treating atrial fibrillation.
        J Atr Fibrillation. 2014; 7: 1103
        • Hong K.L.
        • Glover B.M.
        The impact of lifestyle intervention on atrial fibrillation.
        Curr Opin Cardiol. 2018; 33: 14-19
        • Menezes A.R.
        • Lavie C.J.
        • De Schutter A.
        • et al.
        Lifestyle modification in the prevention and treatment of atrial fibrillation.
        Prog Cardiovasc Dis. 2015; 58: 117-125
        • House C.M.
        • Zhu D.W.
        • Saha M.K.
        • Hamieh T.S.
        • Benditt D.G.
        • Nelson W.B.
        Feasibility of an elective cardioversion service led by advanced practice providers without direct cardiologist supervision.
        Int J Heart Rhythm. 2016; 1: 38-42

      Biography

      Christine Tacklind, MS, ACNP-BC, works at Stanford Cardiac Arrhythmia Service, Stanford Hospital and Clinics in Stanford, CA. She is available at [email protected].